First-ever CRISPR gene-editing drug, made by 2 Boston companies, approved in US

In a first for the Nobel Prize-winning gene-editing technology, a CRISPR-based drug has been approved in the U.S.

The Food and Drug Administration gave the green light Friday to exa-cel, a drug made by two Boston-based companies, Vertex Pharmaceuticals Inc. and CRISPR Therapeutics Inc. It will be marketed under the name Casgevy.

WATCH ANYTIME FOR FREE

>Stream NBC10 Boston news for free, 24/7, wherever you are.

More on this story from Boston Business Journal